Physician profile
Marta Sheremeta
NPI 1255742961
$3,561.25
in general payments reported to CMS, 2019-2025
10 companies · $484 in 2025
The $484 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $160 · 2021: $280 · 2022: $726 · 2023: $202 · 2024: $385 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,070.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $916.52 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Silk Road Medical, INC. | $767.10 | 2019 | |
| Boston Scientific Corporation | $603.32 | 2022-2025 | General - Atherectomy, Enroute Transcarotid Neuroprotection System, Varithena Administration Pack |
| Medtronic Vascular, INC. | $557.10 | 2019 | |
| Medtronic, INC. | $264.91 | 2021-2024 | Heli-Fx Endoanchor System, Endurant Iis |
| Cardiovascular Systems INC. | $179.75 | 2020-2021 | |
| Bolton Medical INC | $147.92 | 2021 | |
| Endologix LLC | $79.78 | 2025 | Endocross Device, Torus Stent Graft System |
| Angiodynamics, INC. | $25.26 | 2025 | Bioflo |
| Ethicon US, LLC | $19.59 | 2024 | Ethicon, Prolene, Vistaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Sheremeta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.